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Abstract
Background: Human hepatocellular carcinoma (HCC) cells express WT1 and/or
carcinoembryonic antigen (CEA) as potential targets for the induction of antitumor immunity. In
this study, generation of cytotoxic T lymphocytes (CTL) and regulatory T cells (Treg) by fusions of
dendritic cells (DCs) and HCC cells was examined.
Methods: HCC cells were fused to DCs either from healthy donors or the HCC patient and
investigated whether supernatants derived from the HCC cell culture (HCCsp) influenced on the
function of DCs/HCC fusion cells (FCs) and generation of CTL and Treg.
Results: FCs coexpressed the HCC cells-derived WT1 and CEA antigens and DCs-derived MHC
class II and costimulatory molecules. In addition, FCs were effective in activating CD4+ and CD8+
T cells able to produce IFN-γ and inducing cytolysis of autologous tumor or semiallogeneic targets
by a MHC class I-restricted mechanism. However, HCCsp induced functional impairment of DCs
as demonstrated by the down-regulation of MHC class I and II, CD80, CD86, and CD83 molecules.
Moreover, the HCCsp-exposed DCs failed to undergo full maturation upon stimulation with the
Toll-like receptor 4 agonist penicillin-inactivated Streptococcus pyogenes. Interestingly, fusions of
immature DCs generated in the presence of HCCsp and allogeneic HCC cells promoted the
generation of CD4+ CD25high Foxp3+ Treg and inhibited CTL induction in the presence of HCCsp.
Importantly, up-regulation of MHC class II, CD80, and CD83 on DCs was observed in the patient
with advanced HCC after vaccination with autologous FCs. In addition, the FCs induced WT1- and
CEA-specific CTL that were able to produce high levels of IFN-γ.
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Journal of Translational Medicine 2008, 6:51 http://www.translational-medicine.com/content/6/1/51Conclusion: The current study is one of the first demonstrating the induction of antigen-specific
CTL and the generation of Treg by fusions of DCs and HCC cells. The local tumor-related factors
may favor the generation of Treg through the inhibition of DCs maturation; however, fusion cell
vaccination results in recovery of the DCs function and induction of antigen-specific CTL responses
in vitro. The present study may shed new light about the mechanisms responsible for the
generation of CTL and Treg by FCs.
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers with a rapidly progressive clinical course and
a poor prognosis [1,2]. Although several treatments such
as tumor resection, liver transplantation, transcatheter
arterial chemoembolization (TAE), and local radiofre-
quency ablation (RFA) are now used to treat HCC, there is
no overall long-term survival benefit so far [3,4]. There-
fore, therapy to prevent the recurrence of HCC is essential.
In this context, immunotherapy represents a potential
approach for eradicating the residual tumors in patients
with HCC. In support of the immunotherapy approach is
the finding that HCC cells overexpress the α-fetoprotein
(AFP), NY-ESO-1, carcinoembryonic antigen (CEA), WT1,
and glypican-3 as potential targets for the induction of
antigen-specific cytotoxic T lymphocytes (CTL) responses
[5-9]. It has been reported that vaccination of HCC
patients is effective for preventing postoperative recur-
rence of HCC [10-12].
Because dendritic cells (DCs) are the most potent antigen
presenting cells (APCs) and attractive vectors for cancer
immunotherapy, the uses of DCs as a booster of antitu-
mor responses have been considered a promising strategy
for cancer vaccine. Different strategies to introduce tumor-
associated antigens (TAAs) into DCs have been applied to
elicit and boost the antitumor immune responses [13-18].
Although clinical trials have demonstrated immunologi-
cal and clinical responses after vaccination with DCs
pulsed with tumor specific peptides, a major drawback of
this strategy comes from a limited number of known
tumor peptides available in many HLA contexts and the
potential evasion of immunological targeting through
their antigens down-regulation. To solve this problem, an
alternative approach has been developed by fusing DCs
with tumor cells [19]. In this approach, a broad spectrum
of TAAs, including those known and unidentified, can be
fully presented by MHC class I and II molecules in the
context of costimulatory molecules [19-25]. Although
vaccination with FCs was associated with immunological
responses, the clinical responses from early clinical trails
in patients with melanoma, glioma, gastric, breast, and
renal cancer was muted [20-33].
CTL play a central role in induction of antitumor immu-
nity. Indeed, a high frequency of CD8+ CTL infiltrating
cancer tissue can be a favorable prognostic indicator in
HCC [34]. However, the progression of tumors despite
the presence of infiltrating CD8+ CTL suggests that immu-
nological tolerance is induced, at least in part, by tumors.
Recent studies have suggested that increased CD4+α chain
of IL-2R (CD25)+ forkhead box P3 (Foxp3)+ regulatory T
cells (Treg) impair the effector function of CD8+ CTL and
are associated with HCC invasiveness [35]. The tumor
microenvironment may play an important role in the
recurrence and survival of HCC. Therefore, the mecha-
nisms by which Treg arise in vivo and exert their immu-
noregulatory effects remain to be defined and are the
subject of intensive investigation.
In the present study, we first show that coculture of T cells
from healthy donors with the fusion cells (FCs) created by
allogeneic HCC cells and immature DCs from the donors
(DCs/allo-HCC) results in activation of both CD4+ and
CD8+ T cells, as demonstrated by high levels of IFN-γ pro-
duction and lysis of the CEA- and/or WT1-positive targets
restricted in HLA-A2 and/or HLA-A24. Interestingly,
fusions of immature DCs generated in the presence of
HCC cell culture supernatants (HCCsp) and allogeneic
HCC (DCs/allo-HCC/sp) induce dysfunction of the fused
cells and promote the generation of CD4+ CD25high
Foxp3+ Treg and impair the induction of antigen-specific
CTL in the presence of the supernatants. Finally, we show
that vaccination of the HCC patient with autologous FCs
(DCs/auto-HCC) is associated with enhanced immuno-
logical responses, as demonstrated by: 1) augmented DCs
function; 2) improved production of IFN-γ in both CD4+
and CD8+ T cells and T-cell proliferation; 3) enhanced
induction of CEA and/or WT1-specific CTL responses; and




K562 cells (American Type Culture Collection) were
maintained in DMEM medium. Colorectal carcinoma cell
lines (COLP-2 and COLM-6) were maintained in TIL
Media I medium (IBL, Takasaki, Japan) [33]. All media
were supplemented with 10% heat-inactivated FCS, 2 mM
L-glutamine, 100 units/ml penicillin, and 0.1 mg/ml
streptomycin.Page 2 of 19
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Monocyte-derived DCs from healthy donors (obtained
with following informed consent and approved by our
institutional review board) were generated. In brief,
peripheral blood mononuclear cells (PBMCs) were pre-
pared from whole blood by Ficoll density-gradient centrif-
ugation. The PBMCs were suspended in tissue culture
flask in RPMI 1640 supplemented with 1% heat inacti-
vated autologous serum for 60 minutes at 37°C to allow
for adherence. The nonadherent cells were removed and
the adherent cells were cultured overnight. To generate
immature DCs (DCs), the nonadherent and loosely
adherent cells were collected on the next day and placed
in RPMI 1640 medium containing 1% heat-inactivated
autologous serum, 1000 U/ml recombinant human GM-
CSF (Becton Dickinson, Bedford, MA, USA), and 500 U/
ml recombinant human IL-4 (Becton Dickinson) for 6
days. To assess the effects of HCCsp on DCs generation,
we have created four types of DC preparation: 1) DCs; 2)
DCs generated in the presence of HCCsp during the entire
culture period (DCs/sp); 3) DCs exposed to 0.1 KE/ml
(0.1 KE equals of 0.01 mg of dried streptococci) penicil-
lin-inactivated Streptococcus pyogenes (OK-432) (Chugai
Pharmaceutical) for 3 days (OK-DCs) as described previ-
ously [25]; 4) OK-DCs generated in the presence of
HCCsp during the entire culture period (OK-DCs/sp).
Four types of DC were generated in the presence of equal
amounts of GM-CSF and IL-4 during the entire culture.
To generate monocyte-derived DCs for vaccination,
PBMCs derived from the HCC patient were freshly iso-
lated (obtained with following informed consent and
approved by our institutional review board). Autologous
DCs were generated in RPMI 1640 medium containing
1% heat-inactivated autologous serum, 1000 U/ml
recombinant human GM-CSF, 500 U/ml recombinant
human IL-4, and 10 ng/ml recombinant TNF-α (Becton
Dickinson) [30]. On day 6 of culture, DCs harvested from
the nonadherent and loosely adherent cells were used for
fusion. The firmly adherent monocytes were harvested
and used as an autologous target for the CTL assays.
HCC cell culture and supernatants
The HCC patient was a 54-year-old man with chronic
active hepatitis based on carrier state of hepatitis B virus
(HBsAg+, HBsAb-, HBeAg-, HBeAb+, HBcAb+, and
HCVAb-). Hepatic resection was carried and histological
examination revealed moderately differentiated HCC.
Specimen from resected HCC (obtained with following
informed consent and approved by our institutional
review board obtained) was isolated and maintained in
TIL Media I medium with 10% heat-inactivated FCS, 2
mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin. The HCC cells were used for fusion cell
preparations created with DCs either from healthy donors
or the HCC patient. The HCC cell culture supernatants
(HCCsp) were collected at 70–80% confluence. After cen-
trifugation at 1200 rpm for 10 min, HCCsp were passed
through a 0.45 um filter. We used HCCsp to investigate
whether HCCsp influence the differentiation of FCs and
their ability to generate CTL or Treg. Moreover, vaccina-
tion with fusions of the patient-derived DCs and autolo-
gous HCC cells was started after 5 month of operation
(with following informed consent and approval of clinical
protocols by our Institutional Review Board (No. 10–33
(2678)).
Fusions of DCs and allogeneic HCC cells
DCs from healthy donors were harvested and mixed with
the HCC cells at a ratio of 10:1. The mixed cell pellets were
gently resuspended in PEG (molecular weight = 1,450)/
DMSO solution (Sigma-Aldrich St. Louis, MO) at room
temperature for 3 to 5 minutes. Subsequently, the PEG
solution was diluted by slow addition of serum-free RPMI
1640 medium. The cell pellets were resuspended in pre-
warmed RPMI 1640 medium supplemented with 10%
heat-inactivated autologous serum containing GM-CSF
and IL-4 for 3 days [27,33]. To examine the effects of
HCCsp on fusion cell generation, fusion cell preparations
were exposed to HCCsp during the entire culture period in
the presence of equal amounts of GM-CSF and IL-4. We
have created four types of FC preparation: 1) DCs fused
with allogeneic HCC cells in the absence of HCCsp during
the entire culture (DCs/allo-HCC); 2) DCs/sp fused with
allogeneic HCC cells in the presence of HCCsp during the
entire culture (DCs/allo-HCC/sp); 3) OK-DCs fused with
allogeneic HCC cells in the absence of HCCsp during the
entire culture (OK-DCs/allo-HCC); and 4) OK-DCs/sp
fused with allogeneic HCC cells in the presence of HCCsp
during the entire culture (OK-DCs/allo-HCC/sp).
Vaccination of the HCC patient with autologous FCs
DCs from the HCC patient were freshly fused with autol-
ogous HCC cells for each vaccination [27,33]. Autologous
FCs were irradiated, suspended in 0.3 ml normal saline,
and underwent up to nine times vaccinations via SC injec-
tion in the left inguinal area at 2-week intervals [29,30].
The number of DCs used for the generation of fusions was
1–2 × 106 in each vaccination. The patient was monitored
and underwent serial measurements of antinuclear anti-
bodies to assess for evidence of autoimmunity.
Phenotype analysis
Cells were incubated with FITC- conjugated Abs against-
CEA (B1.1), MUC1 (HMPV), MHC class I (W6/32), MHC
class II (HLA-DR), B7-1 (CD80), B7-2 (CD86) (BD
Pharmingen), HLA-A2, or HLA-A24 (One Lambda). After
washing with cold PBS, cells were fixed with 2% parafor-
maldehyde. For WT1 staining, cells were permeabilized
(Cytofix/Cytoperm) and stained with FITC-conjugatedPage 3 of 19
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ysis of dual expression, cells were stained with PE- conju-
gated anti-HLA-DR, washed, permeabilized, and
incubated with FITC- conjugated anti-WT1. Cells were
washed, fixed, and analyzed by FACScan (Becton Dickin-
son, Mountain View, CA) with FlowJo analysis software.
T-cell proliferation assay
Nonadherent PBMCs from healthy donors were cultured
with unirradiated DCs/allo-HCC at a ratio of 10:1 for 3
days in the absence of HCCsp in complete RPMI 1640
medium supplemented with 10% heat-inactivated FCS,
100 units/ml penicillin, and 0.1 mg/ml streptomycin.
DCs alone, the HCC cells alone, an unfused mixture of
both DCs and the HCC cells were used as controls. T cells
were purified with nylon wool and cultured for an addi-
tional 4 days in the presence of recombinant human IL-2
(20 units/ml, Shionogi, Osaka, Japan). To assess the
effects of HCCsp on T-cell stimulation, nonadherent
PBMCs were stimulated by unirradiated DCs/allo-HCC/
sp in the presence of HCCsp for 3 days. On day 4 of cul-
ture, T cells were purified with nylon wool and cultured
for an additional 4 days in the presence of recombinant
human IL-2 (20 units/ml). In this case, T cells were cul-
tured in the presence of HCCsp at the initiation and sub-
sequently during the entire culture. Moreover, to assess
the ability of autologous FCs vaccination to stimulate T
cells, PBMCs (before vaccination and one month after the
ninth vaccination) were isolated and cryopreserved in liq-
uid nitrogen in the presence of 10% DMSO/90% autolo-
gous serum. Autologous PBMCs were thawed, washed,
and plated at 1 × 106 cells/well in a 24-well plate. Next
day, nonadherent PBMCs were cocultured with DCs, the
HCC cells, an unfused mixture of both DCs and the HCC
cells, or unirradiated DCs/auto-HCC at a ratio of 10:1 in
the absence of HCCsp for 3 days. On day 4 of culture, T
cells were purified with nylon wool and cultured for an
additional 4 days in the presence of recombinant human
IL-2 (20 units/ml). On day 8 of culture, T cells were cul-
tured in 96-well U-bottomed culture plates at indicated
numbers/well. Dye solution was added to each well and
incubated for 4 hr according to the protocol of Cell Titer
96 Non-radioactive Cell Proliferation Assay Kit (Promega,
Madison, WI). For measurement, we used the Microplate
Imaging System (Bio-Rad, Hercules, CA) at an OD of 550
nm.
CD4+ CD25+ Foxp3+ staining
For analysis of CD4+ CD25+ Foxp3+ T cells, Foxp3 Staining
Kit was used according to manufacture's instructions (BD
Pharmingen). Briefly, T cells were incubated with FITC-
conjugated anti-CD25 mAb (2A3) and PE-Cy-5-conju-
gated anti-CD4 mAb (RPA-T4). After wash, intracellular
staining was performed with PE-conjugated anti-Foxp3
mAb (259D/C7), washed, and analyzed by FACScan (Bec-
ton Dickinson, Mountain View, CA) with FlowJo analysis
software.
IFN-γ and IL-10 production in CD4+ and CD8+ T cells
For analysis of IFN-γ or IL-10 production, each cytokine
secretion assay kit was used according to manufacture's
instructions (Miltenyi Biotec, Auburn, CA). Briefly, T cells
were washed with cold PBS and incubated with cytokine
catching reagent for 5 minutes at 4°C. After incubation,
10 ml of prewarmed complete medium was added with
shaking and cultured for 45 minutes at 37°C. After incu-
bation, cells were labeled with PE-conjugated cytokine
detection antibody for 20 minutes on ice and further
stained with FITC-conjugated anti-CD4 or CD8 mAb
(Miltenyi Biotec) for 20 min on ice. IFN-γ or IL-10 labeled
T cells were washed, fixed and analyzed by two-color FAC-
Scan analysis using CellQuest analysis software (BD Bio-
sciences). The reactivity of CD4+ or CD8+ T cells to
produce IFN-γ is shown as the percentage of the total pop-
ulation of CD4+ or CD8+ T cells that were positive for IFN-
γ.
Pentameric assays
Pentameric assays of soluble class I MHC-peptide com-
plexes were used to detect antigen-specific CTL activity
induced by vaccination with autologous FCs. Complexes
of PE-conjugated HLA-A2-WT1 pentamer (126–134,
RMFPNAPYL), HLA-A2-CEA pentamer (571–579,
YLSGANLNL), or irrelevant pentamer were used (PROIM-
MUNE Oxford, UK). The pentameric staining was per-
formed according to the manufacturer's instructions.
Briefly, the stimulated T cells were incubated with PE-con-
jugated pentamer for 10–15 minutes at room tempera-
ture. After washing with PBS, FITC-conjugated anti-CD8
mAb was incubated for 20–30 minutes at 4°C. Cells were
washed, fixed and analyzed by FACScan using CellQuest
analysis software (BD Biosciences). The reactivity of CD8+
T cells to WT1 or CEA or both are shown as the percentage
of the total population of CD8+ T cells that were double
positive (CD8+pentamer+).
Cytotoxicity assays
The cytotoxicity assays were performed by flow cytometry
CTL assay that was predicted on measurement of CTL-
induced caspase-3 activation in the target cells through
detection of the specific cleavage of fluorogenic caspase-3
using Active Caspase-3 Apoptosis Kit I (BD Pharmingen)
[36,37]. The target cells including the HCC cells, alloge-
neic tumor cell lines, autologous monocytes, and NK-sen-
sitive K562 cells were labeled with the red fluorescence
dye PKH-26 (Sigma, St. Louis, MO). After washing with
PBS, PKH-26-labeled target cells were cultured with T cells
for 2 h at 37°C in 96 well V-bottom plates. In certain
experiments, PKH-26 labeled target cells were pre-incu-
bated with anti MHC class I mAb (W6/32; 1:100 dilu-Page 4 of 19
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addition of effector cells. Cells were washed, fixed with
Cytofix/Cytoperm Solution (BD Pharmingen) and then
washed with Perm/Wash Buffer (BD Pharmingen). Cells
were incubated with FITC-conjugated anti-human Active
Caspase-3 substrate (BD Pharmingen) for 30 minutes at
room temperature, followed by 2 washes with Perm/Wash
Buffer. The percentage of cytotoxicity (mean ± SD of 3 rep-
licates) was determined by the following calculation: per-
centage of Caspase-3 staining = [(Caspase-3+PKH-26+
cells)/(Caspase-3+ PKH-26+ cells + Caspase-3-PKH-26+
cells)] × 100.
Statistical analysis
The Student t test was used to compare various experimen-
tal groups. A p value <0.05 was considered to be statisti-
cally significant.
Results
Phenotypic characterization of DCs generated in the 
presence of HCCsp
Monocyte-derived DCs from healthy donors were gener-
ated in the presence of GM-CSF and IL-4. To assess the
effects of HCCsp on DCs generation, we have prepared
four types of DC preparation; 1) DCs; 2) DCs/sp; 3) OK-
DCs; and 4) OK-DCs/sp. Mean fluorescence intensity
(MFI) of HLA-ABC, HLA-DR, CD80, CD86, and CD83 by
four types of DC was determined by FACS analysis. The
DCs displayed a characteristic phenotype with expression
of HLA-ABC, HLA-DR, costimulatory molecules (CD80
and CD86), but low levels of the maturation marker,
CD83 (Figure 1A). OK-DCs, as compared with DCs,
expressed much higher levels of HLA-DR, CD80, CD86,
and CD83 (Figure 1A). Interestingly, DCs generated in the
presence of the supernatants (DCs/sp) were associated
with down-regulation of antigen presenting molecules,
including HLA-DR, CD80, and CD86 (Figure 1A). To eval-
uate the effects of HCCsp on the activation of DCs, DCs/
sp were also subsequently stimulated with the Toll-like
receptor (TLR) 4 agonist, OK-432 for 3 days (OK-DCs/sp).
OK-DCs/sp, as compared with OK-DCs, exhibited much
lower expression of HLA-ABC, HLA-DR, CD80, CD86,
and CD83. Therefore, even if DCs/sp were exposed to a
stimulus such as OK-432, these DCs could not express full
levels of costimulatory molecules and the maturation
marker in the presence of HCCsp.
Effect of HCCsp on the phenotype of fusion cell 
preparations
To assess the effects of HCCsp on DCs/tumor fusion cell
generation, we have created four types of FC preparation:
1) DCs/allo-HCC; 2) DCs/allo-HCC/sp; 3) OK-DCs/allo-
HCC; and 4) OK-DCs/allo-HCC/sp. DCs displayed a char-
acteristic phenotype with expression of HLA-ABC, HLA-
DR, CD80, CD86, and CD83 molecules (Figure 1A and
2A). However, the HCC cells used for fusion expressed
high levels of WT1 and HLA-ABC and low levels of CEA
but not HLA-DR, CD80, CD86, and CD83 molecules (Fig-
ure 1B, 2A, and 5A). Fusions of DCs to the HCC cells coex-
pressed the HCC cells-derived WT1 antigens and DCs-
derived HLA-DR and costimulatory molecules (Figure 2B
and 2C). The fusion efficiency was determined by dual
expression of tumor marker, WT1, and DC marker, HLA-
DR. The cells positive for both WT1 and HLA-DR in OK-
DCs/allo-HCC increased when compared with those in
DCs/allo-HCC (Figure 2B and 2C). These results support
our previous finding that OK-432 promotes fusion effi-
ciency [25]. However, the percentage of double-positive
cells (WT1 and HLA-DR/CD86) in OK-DCs/allo-HCC/sp
was significantly decreased. These results suggest that sol-
uble factors derived from the HCC cells have detrimental
effect on the expression of maturation molecules of DCs/
tumor fusion cells.
Induction of HCC cells-specific CTL by DCs/allo-HCC
To determine whether HCC cells-reactive T cells are
induced by fusion cells, T cells from healthy donors were
stimulated by fusions of DCs from the same healthy
donors (HLA-A2+) and the HCC cells (HLA-A2+, WT1+,
and CEA+) (DCs/allo-HCC). Cytotoxicity was assessed
with flow cytometry CTL assays that were predicated on
measurement of CTL-induced caspase-3 activation in tar-
get cells through detection of specific cleavage of fluoro-
genic caspase-3 [36,37]. The fusion cells could prime
naive T cells to differentiate into CTL with lytic activity
against the HCC cells (Figure 3A and 3B). After 4 hr coc-
ulture of the HCC cells with healthy donor's T cells stim-
ulated by unirradiated DCs/allo-HCC, the majority of the
HCC cells were detached (Figure 3A, middle panel).
Almost all of the HCC cells were killed after 12 hr incuba-
tion (Figure 3A, right panel). The lysis was inhibited by
preincubation of target cells with an anti-HLA-ABC mAb,
indicating restriction by MHC class I (Figure 3B). By con-
trast, T cells stimulated by an unfused mixture of both
DCs and the HCC cells failed to detach the HCC cells (Fig-
ure 3A).
To assess whether the exposure of HCCsp affects the stim-
ulating ability of fusion cells, the HCC cells were fused to
DCs/sp from healthy donors in the presence of the super-
natants during the entire culture (DCs/allo-HCC/sp). The
fusion cells have inferior ability to stimulate the prolifera-
tion of T cells (Figure 3C) that expressed lower levels of
IFN-γ (Figure 3D) and to induce CTL responses against the
HCC cells (Figure 3E), suggesting that the soluble factors
in the supernatant inhibit the maturation of fusion cells
and have a negative impact in the stimulation of T cells.
To determine the induction of WT1-specitic CD8+ T cells,
a pentameric assay of soluble class I MHC-peptide com-Page 5 of 19
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stimulation with unirradiated DCs/allo-HCC, 8.5 ±
2.18% of CD8+ T cells were positive for WT1 (Figure 3F).
In contrast, the frequency of WT1 pentamer-binding
CD8+ T cells among CD8+ T cells decreased to 1.4 ± 0.08%
when stimulated by unirradiated DCs/allo-HCC/sp in the
presence of HCCsp (Figure 3F). There were no pentamer-
positive CD8+ T cells when control epitope pentamer was
used or T cells were stimulated by an unfused mixture of
DCs and the HCC cells (data not shown). These results
Inhibition of the differentiation of DCs by HCCspFigure 1
Inhibition of the differentiation of DCs by HCCsp. A, We have created four types of DC from four healthy donors; 1) 
DCs; 2) DCs/sp; 3) OK-DCs; and 4) OK-DCs/sp. MFIs of HLA-ABC, HLA-DR, CD80, CD86, and CD83 in four types of DC 
were analyzed. For each group of DCs, the mean ± SD is shown. *, Significant differences. P value (OK-DCs vs OK-DCs/sp) is 
represented. B, MFIs of isotype control, HLA-ABC, HLA-DR, CD80, CD86, and CD83 in the HCC cells were analyzed.Page 6 of 19
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Phenotypic analysis of DCs/allo-HCC fusion cells created in the presence of HCCspFigure 2
Phenotypic analysis of DCs/allo-HCC fusion cells created in the presence of HCCsp. A, Four types of DC were ana-
lyzed by flow cytometry for expression of the indicated antigens (tinted area) B, Four types of FC preparation 1) DCs/allo-
HCC; 2) DCs/allo-HCC/sp; 3) OK-DCs/allo-HCC; and 4) OK-DCs/allo-HCC/sp were analyzed by two-color flow cytometry 
for expression of WT1 and HLA-DR. Numbers represent cells positively staining for the indicated surface markers. C, Percent-
age of cells positive for WT1 and HLA-DR in four types of FC preparation from three healthy donors was analyzed. For each 
group, the mean ± SD is shown. *, Significant differences.
Journal of Translational Medicine 2008, 6:51 http://www.translational-medicine.com/content/6/1/51Figure 3 (see legend on next page)Page 8 of 19
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affected by HCCsp during T cell-stimulation.
Generation of CD4+ CD25high Foxp3+ Treg by DCs/allo-
HCC/sp
To investigate whether HCCsp-exposed fusion cells
induce the generation of CD4+ CD25high Foxp3+ Treg,
nonadherent PBMCs from healthy donors were cocul-
tured with unirradiated DCs/allo-HCC/sp at 10:1 ratio in
the presence of HCCsp. Thereafter, the CD4+ T cells were
gated for analysis of CD25+ population in CD4+ T cells.
Flow cytometry demonstrated that very high levels of
CD25 expression were observed in CD4+ T cells stimu-
lated by unirradiated DCs/allo-HCC, as compared with
those stimulated by unirradiated DCs/allo-HCC/sp. The
low-affinity IL-2 receptor α-chain, CD25 is constitutively
expressed on Treg and is also up-regulated on conven-
tional antigen-activated T cells in the presence of IL-2,
including the vaccine-induced antitumor effector T cells.
Therefore, we examined the Foxp3 expression, a special
marker for Treg [38] to confirm whether these up-regu-
lated CD4+ CD25high T cells are Treg. As shown in Figure
4A, almost all of CD4+ CD25high T cells induced by unirra-
diated DCs/allo-HCC/sp expressed Foxp3 protein in the
presence of HCCsp. Moreover, Foxp3 is also expressed in
CD4+CD25low/- T cells induced by unirradiated DCs/allo-
HCC/sp. In contrast, there was about 50% reduction in
Foxp3 expression among CD4+ CD25high T cells generated
by unirradiated DCs/allo-HCC in the absence of HCCsp
(Figure 4A). We also found that coculture of T cells with
unirradiated DCs/allo-HCC/sp in the presence of HCCsp
caused about 2-fold increase of CD25high+ Foxp3+T cells
among all CD4+ T cells, as compared with those generated
by unirradiated DCs/allo-HCC in the absence of HCCsp
(Figure 4B). Taken together, these results suggest that
DCs/allo-HCC/sp have the tendency to generate CD4+
CD25high Foxp3+ T cells in the presence of the superna-
tants.
Effect of autologous FCs vaccination on the phenotype of 
DCs
The HCC patient was vaccinated with autologous FCs
nine times. Autologous HCC cells expressed high levels of
WT1 and HLA-ABC (HLA-A2+/A24-) and low levels of
CEA but not HLA-DR, costimulatory molecules (CD80
and CD86), and maturation marker, CD83 (Figure 5A).
Before the vaccination and one month after the ninth vac-
cination, PBMCs were collected and frozen in liquid nitro-
gen until analysis. The phenotype of both DCs generated
before and after vaccination was analyzed in the same set
of experiments. After the ninth vaccination, the DCs dis-
played a characteristic phenotype with increased expres-
sion of HLA-DR, CD80, and CD83, as compared with that
obtained before vaccination (Figure 5A and 5B). Before
vaccination, 44.8 and 41.9% of autologous FCs were pos-
itive for WT1 and HLA-DR/CD86, respectively. After vac-
cination, however, the double-positive population was
increased to 57.2 and 57.0%, respectively (Figure 5C).
Immunological responses induced by autologous FCs 
vaccine
The HCC patient was vaccinated nine times and immuno-
logical responses to the autologous vaccination were
investigated. We first assessed the ability of autologous
FCs vaccination to stimulate T cells. After the ninth vacci-
nation, unirradiated DCs/auto-HCC stimulated T-cell
proliferation responses more vigorously than did before
vaccination. (Figure 6A). In addition, unirradiated DCs/
auto-HCC stimulated larger cluster formations of T cells
when compared with those obtained before vaccination
(Figure 6B). Furthermore, coculture of T cells obtained
after vaccination with DCs/auto-HCC resulted in an evo-
Induction of HCC cells-specific CTL by DCs/allo-HCCFig re 3 (see previous pag )
Induction of HCC cells-specific CTL by DCs/allo-HCC. A, Nonadherent PBMCs from healthy donors stimulated by 
unirradiated DCs/allo-HCC (upper panel) or DCs mixed with allo-HCC cells (lower panel) were cocultured with the HCC 
cells at a ratio of 10:1. After 4 hr culture, cells were examined under a microscope. After 12 hr culture, floating cells were har-
vested and adherent cells were examined (magnification, ×20) (magnification, × 100 in upper corner panel). B, T cells stimu-
lated by unirradiated DCs/allo-HCC were cocultured with PKH26-labeled allo-HCC cells at the indicated ratios. Target cells 
were preincubated with control IgG (solid circles) or anti-MHC class I mAb (W6/32; 1:100 dilution, open circles).C, T cells 
were stimulated with 2 types of fusion cell preparation from three healthy donors: 1) unirradiated DCs/allo-HCC in the 
absence of HCCsp (■) and 2) unirradiated DCs/allo-HCC/sp in the presence of HCCsp (). T-cell proliferation assay was per-
formed by Cell Titer 96 Nonradioactive Cell Proliferation Assay Kit according to the protocol. D, After stimulation with the 2 
types of fusion cell preparation from four healthy donors, percentage of IFN-γ-positive CD4+ or CD8+ T cells was assessed. E, 
After stimulation with the 2 types of fusion cell preparation from three healthy donors, T cells were incubated with PKH-26 
labeled allo-HCC cells at a ratio of 60:1. Percentage of cytotoxicity (mean ± SD of 3 replicates) was determined by flow cytom-
etry-CTL assay. F, After stimulation with the 2 types of fusion cell preparation, CD8+ T cells (HLA-A2+) from three healthy 
donors were analyzed by HLA-A2/WT1 pentameric assay. CD8+ T cell reactivity to WT1 was shown as the percentage of 
double-positive population (CD8+ pentamer+) among all CD8+ T cells. For each group, the mean ± SD of three experiments 
is shown. *, Significant differences.Page 9 of 19
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Generation of CD4+ CD25+Foxp3+ Treg in the presence of HCCspFigure 4
Generation of CD4+ CD25+Foxp3+ Treg in the presence of HCCsp. A, Nonadherent PBMCs were stimulated with 
unirradiated DCs/allo-HCC in the absence of HCCsp (right panel) or unirradiated DCs/allo-HCC/sp in the presence of HCCsp 
(left panel). On day 4, T cells were purified, cultured, and analyzed by 3-color flow cytometry for expression of CD4, CD25, 
and Foxp3. Three different populations; a) CD4+CD25high T cells; b) CD4+CD25low T cells; c) CD4+CD25- T cells were gated 
to analyze Foxp3 expression. Numbers represent cells positively staining for the indicated surface markers. Similar results 
were obtained in three individual experiments. B, Nonadherent PBMCs from three healthy donors were stimulated with unir-
radiated DCs/allo-HCC in the absence or presence of HCCsp. Naive PBMCs from three healthy donors were also cultured in 
the absence or presence of HCCsp. CD4+ T cells were gated to analyze CD25high Foxp3+ expression and the percentage of 
CD25highFoxp3+ in CD4+ population was shown. For each group, the mean ± SD is shown. *, Significant differences.
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Phenotypic characterization of DCs/auto-HCCFigure 5
Phenotypic characterization of DCs/auto-HCC. A, Autologous HCC cells (auto-HCC) and DCs generated before and 
after vaccination were analyzed by flow cytometry for expression of the indicated antigens. Thin line, isotype control; thick line, 
indicated antigens. Numerical values show the MFIs of indicated antigens in DCs. B, MFIs of HLA-ABC, HLA-DR, CD80, CD86, 
and CD83 in DCs generated before and after vaccination were analyzed. C, Fusions of auto-HCC and DCs (before or after 
vaccination) were analyzed by 2-color flow cytometry for dual expression of WT1 and HLA-DR/CD86. Numbers represent 
cells positively staining for the indicated surface markers.
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The ability of vaccination with autologous FCs to stimulate T cellsFigure 6
The ability of vaccination with autologous FCs to stimulate T cells. A, Nonadherent PBMCs obtained before and after 
vaccination were stimulated with unirradiated DCs/auto-HCC, DCs, auto-HCC cells, or an unfused mixture of both for 7 days. 
T-cell proliferation assay was performed by Cell Titer 96 Nonradioactive Cell Proliferation Assay Kit according to the proto-
col. B, Nonadherent PBMCs obtained before and after vaccination were stimulated with unirradiated DCs/auto-HCC and 
examined under a microscope (magnification, ×10). Similar results were obtained in three individual experiments. C, Nonad-
herent PBMCs obtained before (left panel) and after vaccination (right panel) were stimulated with unirradiated DCs/auto-
HCC and stained with FITC-conjugated anti-CD4 and PE-conjugated anti-CD8 mAb. Numbers represent cells positively stain-
ing for the indicated surface markers. D, Nonadherent PBMCs obtained before (left panel) and after vaccination (right panel) 
were stimulated with unirradiated DCs/auto-HCC. Percentage of IFN-γ-positive CD4+ or CD8+ T cells was assessed. For each 
group, the mean ± SD of three experiments is shown.
Journal of Translational Medicine 2008, 6:51 http://www.translational-medicine.com/content/6/1/51lution of CD8+ T cell populations from 5.34% to 18. 89%
in vitro (Figure 6C). In contrast, autologous DCs or the
HCC cells were not able to stimulate the T cells (Figure
6A).
We next examined the quality of CD4+ and CD8+ T cells
from the HCC patient vaccinated by autologous FCs.
When nonadherent PBMCs obtained before vaccination
were restimulated with unirradiated DCs/auto-HCC in
vitro, the expression of IFN-γ in both CD4+ and CD8+ T
cells were much lower (Figure 6D). In contrast, the expres-
sion of IFN-γ in CD4+ and CD8+ T cells significantly
increased after vaccination (Figure 6D). The low levels of
IL-10 expression in T cells did not impair the production
of IFN-γ (data not shown). These results suggest that vac-
cination with autologous FCs improves the immune
responses in the patient.
Induction of HCC cells-specific CTL by vaccination with 
autologous FCs
We next examined whether fusion cell vaccination could
augment the induction of HCC cells-specific CTL in the
patient. Before vaccination, coculture of nonadherent
PBMCs with unirradiated DCs/auto-HCC resulted in low
levels of CTL induction against autologous HCC cells in
vitro (Figure 7A). However, the CTL responses against
autologous HCC cells were significantly augmented after
vaccination (Figure 7A and 7B). Preincubation of the
autologous HCC cells with anti-HLA-ABC mAb inhibited
the lysis, suggesting the MHC class I restriction (data not
shown). In contrast, there was minimal lysis of autolo-
gous HCC cells by nonadherent PBMCs obtained before
vaccination cocultured with the HCC cells lysates, an
unfused mixture of DCs and the HCC cells (Figure 7A),
DCs alone, or the HCC cells alone (data not shown).
Moreover, nonadherent PBMCs obtained after vaccina-
tion stimulated with the HCC cells lysates have consider-
able cytotoxic activity while no cytotoxicity is observed
using those obtained before vaccination (Figure 7A).
These results suggest that vaccination with autologous FCs
has the potential to increase CTL precursors against autol-
ogous HCC cells in the patient.
To assess the antigen specificity and HLA restriction ele-
ments of CTL induced by vaccination with autologous FCs
(HLA-A2+/A24-), we used CTL assay using autologous
HCC cells and multiple allogeneic cell lines as targets. As
shown in Figure 7B, T cells from after vaccination stimu-
lated by unirradiated DCs/auto-HCC lysed not only the
HCC cells (HLA-A2+/A24-, WT1+, and CEA+) but also
HLA class I-semimatched colorectal carcinoma cell line,
COLP-2 (HLA-A2+/A24-) endogenously expressing WT1
and CEA. By contrast, no lysis of allogeneic colorectal car-
cinoma cell line, COLM-6 (HLA-A2- and A24-, WT1+ and
CEA+) was observed, suggesting that HLA-A2 was, at least
in part, the restriction element of CTL (Figure 7B). In addi-
tion, CTL induced by unirradiated DCs/auto-HCC did not
lyse autologous monocytes or NK-sensitive K562, indicat-
ing the selectivity for lysis of autologous HCC cells (Figure
7B). Furthermore, the pentameric assay confirmed that
the population of WT1- and CEA-reactive CD8+ T cells was
augmented by the fusion cell vaccination. Before vaccina-
tion, coculture of nonadherent PBMCs with unirradiated
DCs/auto-HCC resulted in 1.06% of WT1- and 0.41% of
CEA- reactive CD8+ T cells in HLA-A2 restrictive manner
(Figure 7C). In contrast, about 2-fold increase in the per-
centage of WT1- and CEA-reactive CD8+ T cells was
observed after the ninth vaccination. No positive T cells
were detected when an irrelevant pentamer was used or
minimal antigen-positive T cells were detected when T
cells were cocultured with DCs alone, the HCC cells alone,
or an unfused mixture of DCs and the HCC cells in vitro
(data not shown). Taken together, these results indicate
that vaccination with autologous FCs is able to enhance
the induction of WT1- and CEA-reactive CD8+ T cells.
Discussion
The present study provides first evidences that soluble fac-
tors derived from the HCC cells inhibit maturation of DCs
and DCs/tumor fusion cells. These fusion cells, in turn,
promote the induction of CD4+ CD25high Foxp3+ Treg and
impair induction of antigen-specific CTL. Although DCs
from the patient with advanced HCC exhibit functional
impairment, fusion cell vaccine improves DCs function
and induces augmented antigen-specific polyclonal CTL.
Because the HCC patient had chronic active hepatitis
based on carrier state of hepatitis B virus, the immune
responses may be poorly reactive to autologous HCC
cells. DCs from hepatitis B virus (HBV) carriers have been
reported to exhibit functional impairment [39]. Possible
explanations for this phenomenon are infection of HBV
into DCs or alteration of DCs function by HBV and HCC
itself [39]. This process is mostly related to HCC-derived
soluble factors, several of which have been identified.
Decreased function of DCs is one potential mechanism by
which tumor evade the host's immune responses. Imma-
ture DCs are one of the mediators of tolerance induction.
In peripheral lymphoid organs immature DCs are incapa-
ble of mobilizing CTL responses and have been reported
to induce tolerance. In contrast, if a stimulus for DCs acti-
vation is sufficiently coadministered with antigens,
mature DCs express high levels of costimulatory mole-
cules, resulting in priming of antigen-specific CTL induc-
tion rather than Treg [25]. Therefore, we investigated
whether supernatants derived from the HCC cells affect
the function and maturation of DCs. The data show that
exposure of immature DCs to the supernatants results in
down-regulation of HLA-DR and costimulatory molecules
(CD80), and maturation marker (CD83). The down-regu-Page 13 of 19
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Induction of CEA- and WT1-reactive T cells by vaccination with autologous FCsFig re 7
Induction of CEA- and WT1-reactive T cells by vaccination with autologous FCs. A, Nonadherent PBMCs obtained 
before (left panel) and after vaccination (right panel) were stimulated with auto-HCC cells lysates, DCs mixed with auto-HCC, 
or unirradiated DCs/auto-HCC. T cells were cocultured with the HCC cells at a ratio of 60: 1. B, Nonadherent PBMCs 
obtained before (left panel) and after vaccination (right panel) were stimulated by unirradiated DCs/auto-HCC. T cells were 
cocultured with the HCC cells, COLP-2, COLM-6, K562, or autologous monocytes at a ratio of 20:1. Percentage of cytotoxic-
ity (mean ± SD of 3 replicates) was determined by flow cytometry-CTL assay. C, Nonadherent PBMCs (HLA-A2+/A24-) 
obtained before (left panel) and after vaccination (right pane) were stimulated with unirradiated DCs/auto-HCC. T cells were 
analyzed by HLA-A2/WT1 or HLA-A2/CEA pentameric assay. *, Significant differences.
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may have negative effects in the interaction between T
cells and DCs at the first phase of immunological synapse
formation, hence decreasing the DC-dependent T-cell
activation and proliferation in patients with advanced
HCC. TLR agonists are potent activators of innate immune
responses, inducing DCs maturation and inflammatory
cytokine secretion by innate immune cells and as a conse-
quence they promote antitumor immune responses when
coadministered with antigens. It has been demonstrated
that OK-432 promotes functional maturation of DCs
through the TLR4 pathway to enhance antigen-specific
CTL responses [25,40].
Lipopolysaccharide (LPS)-mediated TLR4 signaling also
leads to maturation of DCs [25,40]. However, clinical use
of LPS is limited due to potential toxicity. On the other
hand, OK-432 is an agent of good manufacturing practice
grade and has been widely used in patients with cancer
[25,40]. Therefore, we have used OK-432 to stimulate
immature DCs to determine whether the HCC cell culture
supernatants have suppressive effects on DCs maturation.
Immature DCs generated in the presence of the superna-
tants were unable to become fully mature after OK-432
stimulation, suggesting that administration of OK-432
alone cannot sufficiently help to induce DCs maturation
in the presence of the immunosuppressive molecules pro-
duced by the HCC cells. This phenomenon is consistent
with previous findings that tumor cells secrete many
immunosuppressive cytokines and chemokines (IL-6, IL-
10, and TGF-β) [41,42].
Moreover, tumor cells also secrete molecules such as AFP
and MUC1, all of which affect the maturation and func-
tion of DCs [43,44]. In this study, the HCC cells used for
fusion cell vaccination secrete low levels of TGF-β but no
AFP, PIVKA-II, and MUC1 (data not shown). A recent
study that has reported that DCs exposed with superna-
tants derived from HCC cell lines culture fail to undergo
full maturation upon stimulation with LPS [45], also sup-
port our findings. Thus, if a stimulus for DCs activation is
insufficiently administrated in the presence of the immu-
nosuppressive molecules, DCs may fail to undergo full
maturation, leading to induction of tolerance in patients
with advanced HCC. Combined TLR agonists may be par-
ticularly essential for the full maturation of DCs in the
local tumor microenvironment of cancer patients. In the
present study, autologous fusion cells for vaccination
were stimulated by TNF-α, but DCs used for the preclini-
cal study were matured by OK-432. It has been reported
that OK-432 promotes more functional maturation of
DCs than that obtained with either LPS or a standard mix-
ture of cytokines (TNF-α, IL-1β, IL-6, and PGE2) [25,46].
Therefore, even if we have used TNF-α in the preclinical
study, similar results may be obtained in this experimen-
tal setting.
It has been reported that efficient CTL induction, which is
particularly important in antitumor responses, required
the stimulation of both CD4+ and CD8+ T cells [47]. Pre-
viously, we have reported that immature DCs fused with
allogeneic tumor cell line present multiple TAAs and
induce antitumor immunity against autologous tumor
cells [33]. In this allogeneic human tumor cell line model,
antigen-specific CTL responses induced by fusions of allo-
geneic tumor cell line and immature DCs have the same
potency as those induced by fusions of autologous tumor
cells and immature DCs in vitro [33]. Thus, to assess the
functional capacity of fusion cells created from the HCC
cells and DCs to stimulate CTL, we first fused the patient-
derived HCC cells to immature DCs generated from
healthy donors (DCs/allo-HCC) in the absence of the
HCC cell culture supernatants. Donor's CD4+ and CD8+ T
cells were strongly stimulated by DCs/allo-HCC with high
levels of IFN-γ production, suggesting that antigens were
presented through both MHC class I and class II pathways
simultaneously. However, the INF-γ production and T-cell
proliferation were abolished in CD4+ and CD8+ T cells
primed by DCs/allo-HCC/sp in the presence of the super-
natants. It could be argued whether the supernatants have
a suppressive effect on DCs/allo-HCC/sp, on the stimula-
tion of T cells by them, or an additive effect at both levels.
Culture of naive PBMCs from healthy donors in the pres-
ence of the supernatants impaired T-cell proliferation
(data not shown), suggesting that the supernatants have,
at least in part, a suppressive effect on stimulation of T
cells. Moreover, fusion cells created in the presence of the
supernatants have an impaired characteristic phenotype
and failed to undergo full activation upon stimulation
with OK-432, suggesting that the supernatants also
exhibit functional impairment of the fusion cells as APCs
in the patient. OK-432 alone may be still insufficient to
stimulate fusion cells in the local tumor microenviron-
ment of the patient. In addition, DCs/allo-HCC/sp dual-
expressed both WT1 and HLA-DR/CD86 at significantly
lower levels than those obtained from DCs/allo-HCC,
therefore, could not be optimal for CD4+ and CD8+ T cell
stimulation in vitro. Because the levels of fusion efficiency
are also closely correlated with antitumor immunity in a
murine study (our unpublished data), the presence of the
soluble factors may prevent the efficient induction of anti-
tumor immunity. Recent studies that have demonstrated
that HCC cell lines culture supernatants impaired thera-
peutic efficacy of the vaccine in tumor-bearing mice
[45,48], support our findings that the supernatants impair
the induction of CTL in vitro.
Important issues that must be addressed are how the HCC
cell culture supernatants exert suppressive effects on CTLPage 15 of 19
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cells-derived soluble factors promote the induction of tol-
erance through the generation of CD4+ CD25highFoxp3+
Treg subset, which is linked to compromised immune
responses in patients with HCC [49,50]. Indeed, the
potent immunosuppressive effects of Treg can explain the
failure of many immunotherapeutic approaches to cancer
[49]. Whether CD4+ CD25high Treg (naturally occurring
Treg) are recruited from thymus and accumulated in HCC
or whether HCC cells-derived soluble factors convert
CD4+ CD25- T cells to CD4+ CD25high Treg in the periph-
ery are currently unclear. In either way, HCC cells-derived
soluble factors might play a central role in immune sup-
pression mediated by Treg, suggesting that these factors
interfere with DCs/tumor fusion approach and inhibit
antitumor immune responses in patients with advanced
HCC. Moreover, it has recently been reported that DCs are
capable of inducing conversion of naive CD4+ T cells to
adaptive CD4+ CD25+ Foxp3+ Treg in the presence of TGF-
β [51]. The HCC cells used for fusions in the present study
secrete low levels of TGF-β. Interestingly, coculture of
nonadherent PBMCs from healthy donors with DCs/allo-
HCC/sp in the presence of the supernatants resulted in
generation of Treg. The abnormal function of DCs and dif-
ferentiation into Treg in the local tumor microenviron-
ment of the patient with advanced HCC may be due to the
combined effects of numerous immunosuppressive
cytokines and chemokines [45,48]. Although the effect of
the HCC cell supernatants in the generation of Treg in
vitro is demonstrated in the present study, little is known
about the impact of fusion cell vaccination on generating
Treg. The negative impact of fusion cell vaccine is still not
clear in this experimental setting. A recent study has dem-
onstrated that vaccination with DCs/tumor fusion cells
producing TGF-β resulted in the induction of Treg in vivo
and in vitro in a murine model [52].
Moreover, the blockade of TGF-β reduces Treg induction
by the fusion cell vaccine and enhances antitumor immu-
nity [52]. Depletion of human Treg before vaccination
may also lead to enhanced antitumor immune responses
in cancer patients [53]. If the immune suppressed envi-
ronment in tumor is sufficiently improved, approaches
for selective manipulation of the innate immune
responses induced by combined TLR agonists may have
more potential to promote DCs maturation and CTL over
Treg generation [54]. Patients early in the course of the
disease with low tumor burden and still an uncompro-
mised immune system are expected to respond best to
clinical responses by fusion cell vaccination.
Because DCs from the patient with advanced HCC exhibit
functional impairment, the patient is poorly immune
reactive to autologous tumor, as compared with healthy
donors. Inhibition of DCs maturation could represent a
frequent mechanism by which tumor cells will escape
immune recognition. However, vaccination of the HCC
patient with autologous fusion cells resulted in enhanced
expression of HLA-DR, costimulatory molecules (CD80),
and maturation marker (CD83) on DCs. The vaccination
could recover functional impairment of DCs in the HCC
patient. A recent study also has reported that the use of
DCs-based cancer vaccines induces recovery of DCs func-
tion in metastatic cancer patients [55]. We also found
before vaccination low levels of IFN-γ production in both
CD4+ and CD8+ T cells, which were poorly reactive to
autologous HCC cells. However, fusion cell vaccination
elicited up-regulated production of IFN-γ in T cells.
Importantly, coculture of nonadherent PBMCs obtained
after vaccination with autologous fusion cells resulted in
augmented CTL responses against autologous HCC cells,
as compared with those obtained before vaccination. In
addition, nonadherent PBMCs obtained after vaccination
stimulated with even the HCC cells lysates have consider-
able levels of cytotoxic activity while no cytotoxicity is
observed in those obtained before vaccination. Although
the results from CTL assays are influenced by the in vitro
stimulation procedures [56], it is reasonable to speculate
that fusion cell vaccine can increase numbers of CTL pre-
cursor in the HCC patient. Interestingly, more than 2-fold
increase of CTL responses specific for WT1 and CEA were
observed after vaccination. Induction of antigen-specific
polyclonal CTL is particularly important for eradicating
tumor cells [24]. Thus, the multiple doses of vaccination
may also have the potential to stimulate both CD4+ and
CD8+ T cells and result in induction of antigen-specific
polyclonal CTL responses in the patient.
Although hepatic lesions remained to be stable during
vaccination, pulmonary metastases showed progression
and died after seven month from the first vaccination. In
spite of the immunological responses, defects of the clin-
ical responses in the patient with advanced HCC may be
caused by the immunosuppressive influences derived
from tumor as shown in the present experimental setting.
Even if HCC cells-specific CTL responses were observed in
this study, CTL directed against the tumor might become
functionally inactive when exposed to the local tumor
microenvironment [39]. It has been shown that T cells in
HCC lesions appear to contain Treg that accumulate
locally and inhibit CTL responses [50]. Our in vitro results
also support this notion and show that the HCC cell cul-
ture supernatants impair the DCs maturation, even if OK-
432 is administrated, resulting the generation of Treg in
vitro. The lack of therapeutic efficacy with fusion cell vac-
cine in the patient may be not due to low levels of CTL
response but inhibitory activity by Treg. The HCC tissues
are much more complex than the present experimental
setting. Tumor tissues comprise not only of tumor cells
but also of tumor-associated fibroblasts, vascularPage 16 of 19
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ety of immune cells (DCs, macrophages, granulocytes,
and NK cells), all of which are key regulators in tumori-
genesis [57,58]. It has been demonstrated that tumor-
associated fibroblasts and macrophages synthesize pro-
teins, such as VEGF, TGF-β, and IL-10, all of which con-
tribute to the local immunosuppressive environment [57-
59]. Therefore, tumor rejection also can be achieved by
modulation of tumor-stromal fibroblasts or by distur-
bance of the network [60,61]. Further studies are required
to determine the inhibitory interactions among these cells
and their secretary molecules on DCs differentiation and
Treg generation.
The vaccine administrated to this HCC patient is fusions
of autologous whole HCC cells and DCs; therefore, con-
cern exists regarding the possible induction of hepatitis by
this vaccination. However, no hepatitis was induced, as
evidenced by the constant levels of serum AST and ALT. In
the present study, vaccination of the HCC patient could
be performed safely without significant adverse effects
associated with the vaccination. To date, in reports on
fusion cell vaccination, severe autoimmune diseases have
not been induced by the treatment [28-32].
Conclusion
Our results demonstrate that fusion cell vaccination can
improve DCs function and induce CTL. However, super-
natants derived from the HCC cells promoted the genera-
tion of Treg with enhanced immunosuppressive capacities
in vitro. Treg may contribute to the attenuated CTL
responses in the presence of the supernatants. A major
obstacle to the development of any active immunothera-
peutic approach to cancer is the immunosuppressive envi-
ronment of the growing tumor. A combination of control
of Treg and concomitant induction of CTL may be a more
effective immunotherapy to reduce recurrence and pro-
long survival after surgery.
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